Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Structure Therapeutics Inc. - American Depositary Shares (NQ:GPCR)

29.77 -1.50 (-4.78%)
Delayed Quote Updated: 1:56 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 995,689
Open 31.27
Bid (Size) 29.75 (500)
Ask (Size) 29.79 (200)
Prev. Close 31.27
Today's Range 29.77 - 31.39
52wk Range 24.99 - 94.90
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Structure Therapeutics Advances Weight-Loss Pills With New Clinical Data ↗
Structure Therapeutics (NASDAQ: GPCR) reports strong clinical trial data for oral weight loss candidates ACCG-2671 and aleniglipron. 
Via Benzinga
News headline image
Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management
From Structure Therapeutics Inc.
Via GlobeNewswire

Performance

YTD
-56.3%
-56.3%
1 Month
-35.1%
-35.1%
3 Month
-42.9%
-42.9%
6 Month
-40.7%
-40.7%
1 Year
+6.3%
+6.3%

More News

Read More
News headline image
Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences
From Structure Therapeutics Inc.
Via GlobeNewswire
News headline image
Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
News headline image
Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity
From Structure Therapeutics Inc.
Via GlobeNewswire
News headline image
Structure Therapeutics Announces Participation in Upcoming Investor Conferences
From Structure Therapeutics Inc.
Via GlobeNewswire
News headline image
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Monashee Scales Back Its Bet on Structure Therapeutics ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
News headline image
Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions
From Structure Therapeutics Inc.
Via GlobeNewswire
News headline image
3 Ways to Invest in the Growing GLP-1 Weight Loss Market ↗
Via MarketBeat
News headline image
Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel
From Structure Therapeutics Inc.
Via GlobeNewswire
News headline image
The Great Metabolic Land Grab: Why Viking and Structure Have Become Big Pharma’s 'Irresistible' Targets
Via MarketMinute
Topics Intellectual Property
News headline image
Eli Lilly Secures Landmark FDA Approval for Oral Weight-Loss Pill, Sending Shares Soaring
Via MarketMinute
Topics Economy
News headline image
Main Street’s Revenge: The Great Rotation of 2026 Rewrites Market History
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
The Great Rotation: Small-Caps Seize Market Leadership in Historic 2026 Breakout
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
The Great Rotation: Russell 2000 Outshines Mega-Caps as Domestic Small-Caps Take the Reins in 2026
Via MarketMinute
Topics Artificial Intelligence Economy World Trade
News headline image
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges ↗
Via The Motley Fool
News headline image
3 Companies at the Forefront of the GLP-1 Pill Wars ↗
Via MarketBeat
News headline image
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
From Structure Therapeutics Inc.
Via GlobeNewswire
News headline image
Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The Valuation Reset: A Deep-Dive into Novo Nordisk (NVO) in 2026
Via Finterra
Topics Economy Intellectual Property

Frequently Asked Questions

Is Structure Therapeutics Inc. - American Depositary Shares publicly traded?
Yes, Structure Therapeutics Inc. - American Depositary Shares is publicly traded.
What exchange does Structure Therapeutics Inc. - American Depositary Shares trade on?
Structure Therapeutics Inc. - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Structure Therapeutics Inc. - American Depositary Shares?
The ticker symbol for Structure Therapeutics Inc. - American Depositary Shares is GPCR on the Nasdaq Stock Market
What is the current price of Structure Therapeutics Inc. - American Depositary Shares?
The current price of Structure Therapeutics Inc. - American Depositary Shares is 29.77
When was Structure Therapeutics Inc. - American Depositary Shares last traded?
The last trade of Structure Therapeutics Inc. - American Depositary Shares was at 10/01/26 01:56 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.